.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Patricia Pozo-Rosich

Invited speaker

07.12.2022
13:05 – 13:25 15 Min. 5 Min.
Invited lecture
COVID and headache
08.12.2022
09:00 – 09:30 30 Min. 0 Min.
Invited lecture
Epigenetics and migraine

Vortrag

07.12.2022
14:15 – 14:16 1 Min. 0 Min.
On Demand
Covid-19 and vaccines related headaches and cluster headache
08.12.2022
09:30 – 09:31 1 Min. 0 Min.
On Demand
Hormones and headache – What's new?
09.12.2022
16:15 – 16:20 3 Min. 2 Min.
ePoster
P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
Migraine
09.12.2022
16:20 – 16:25 3 Min. 2 Min.
ePoster
P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
Migraine
09.12.2022
16:45 – 16:50 3 Min. 2 Min.
ePoster
P135
Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
Migraine

Weitere Beteiligungen

08.12.2022
16:10 – 16:15 3 Min. 2 Min.
ePoster
P73
Clinical manifestations and impact of SARS-CoV-2 infections and vaccines in patients with migraine
COVID and headache, Migraine
08.12.2022
18:45 – 18:55 8 Min. 2 Min.
Abstract lecture
A24
Salivary CGRP and erenumab response: towards precision medicine in migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:35 – 15:40 3 Min. 2 Min.
ePoster
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Migraine
09.12.2022
15:40 – 15:45 3 Min. 2 Min.
ePoster
P244
Interest in headache and other neurological subspecialties among neurology residents in Denmark: a nationwide survey
Epidemiology, Guidelines in headache
09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Migraine
09.12.2022
15:50 – 15:55 3 Min. 2 Min.
ePoster
P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
15:55 – 16:00 3 Min. 2 Min.
ePoster
P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Migraine
09.12.2022
16:00 – 16:05 3 Min. 2 Min.
ePoster
P144
Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis.
Migraine
09.12.2022
16:05 – 16:10 3 Min. 2 Min.
ePoster
P145
Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:10 – 16:15 3 Min. 2 Min.
ePoster
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Migraine
09.12.2022
16:15 – 16:20 3 Min. 2 Min.
ePoster
P129
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
Migraine
09.12.2022
16:15 – 16:20 3 Min. 2 Min.
ePoster
P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
Migraine
09.12.2022
16:15 – 16:20 3 Min. 2 Min.
ePoster
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:20 – 16:25 3 Min. 2 Min.
ePoster
P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
Migraine
09.12.2022
16:25 – 16:30 3 Min. 2 Min.
ePoster
P131
Assessing Hypersensitivity, Cortical Hyperexcitability, and Habituation in Migraine, according to Age and Disease Severity, using Visual Evoked Potentials during Pattern-Reversal Stimulation
Migraine
09.12.2022
16:35 – 16:40 3 Min. 2 Min.
ePoster
P133
Quantifying aversion thresholds to light, sound, smell, and touch in migraine: A longitudinal study in migraine and non-headache controls
Basic science, animal models in headache research, Migraine
09.12.2022
16:35 – 16:40 3 Min. 2 Min.
ePoster
P168
Impact of air pollution exposure on headache onset in migraine patients
Data science in research and digital medicine, Migraine
09.12.2022
16:35 – 16:40 3 Min. 2 Min.
ePoster
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:45 – 16:50 3 Min. 2 Min.
ePoster
P135
Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
Migraine
09.12.2022
16:55 – 17:00 3 Min. 2 Min.
ePoster
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Migraine
10.12.2022
08:50 – 09:00 8 Min. 2 Min.
Abstract lecture
A41
Do novel European Headache Federation criteria identify differences in migraine burden? Baseline data of an international real-life study on resistant and refractory migraine (REFINE).
Guidelines in headache, Migraine
10.12.2022
09:00 – 09:10 8 Min. 2 Min.
Abstract lecture (online)
A42
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a Real-Life European Multicenter Study
Headache in the elderly, Migraine